Our mission is to become a transnational pharmaceutical company through the development and introduction of a wide portfolio of branded and generic products in key markets.
Lupin Pharmaceuticals, Inc. entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil.
We are very pleased to be able to bring Suprax® an important anti-infective product in pediatric practice, back to the US market.
We are recognized as a leading manufacturer of cephalosporin API's, with FDA approval to manufacture complex oral and injectable cephalosporins.
Lupin is amongst the world's largest manufacturers of products in its chosen therapeutic areas.
Lupin Receives FDA Approval for Generic Celebrex® Capsules
Lupin Announces Strategic Alliance for Emerging Markets
Lupin and Salix Announce Exclusive Distribution Agreement for Canada,Zaxine®, Relistor® and Other Gastroenterology Products
Lupin Launches Generic Cipro® for Oral Suspension in the US
Lupin Inks Strategic Joint Venture Agreement with Yoshindo Inc
Lupin Appoints Theresa Stevens as Chief Corporate Development Officer.
manufacturing / r&d
Copyright © 2010, Lupin Pharmaceuticals, Inc., All Rights Reserved.